Last €5.28 EUR
Change Today +0.10 / 1.93%
Volume 1.3K
ALINT On Other Exchanges
EN Paris
As of 10:04 AM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

integragen (ALINT) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/21/14 - €10.37
52 Week Low
09/20/13 - €3.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for INTEGRAGEN (ALINT)

Related News

No related news articles were found.

integragen (ALINT) Related Businessweek News

No Related Businessweek News Found

integragen (ALINT) Details

IntegraGen S.A., a biotechnology company, focuses on the development and commercialization of molecular diagnostic tests in France. The company develops biomarkers for use as diagnostic tools in the fields of autism, oncology, diabetes, and obesity. It offers DNA extraction, sample management, and storage services; NextGen sequencing services; SNP genotyping services; and methylation analysis, including DNA sample reception and QC, bisulfite conversion, genotyping analysis, data quality control, delivery of methylation value, and delivery of genome studio project file for data analysis with genome studio software. The company was founded in 2000 and is headquartered in Evry, France.

32 Employees
Last Reported Date: 04/30/14
Founded in 2000

integragen (ALINT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

integragen (ALINT) Key Developments

IntegraGen Presents Data on New Version of ARISk(R) Test

IntegraGen announced that it has presented data during the 2014 International Meeting for Autism Research (IMFAR) held in Atlanta, Georgia reporting the results of a study which permits the ability to predict the risk of autism spectrum disorder (ASD) in children with signs of developmental delay or autism. The study identified over 1,700 common genetic variants which were shown to be associated with the risk of autism. The present study, which included nearly 3,000 individuals diagnosed with ASD and 3,000 controls, builds on previous research the company conducted which identified single-nucleotide polymorphisms (SNPs) that permit the ability to predict the risk of autism in children who have an older sibling diagnosed with ASD The Centers for Disease Control (CDC) has recently reported that it estimates that the prevalence of ASD in the U.S. is 1 in 68 children, a 30% increase in the two year period since the previous CDC report. The CDC has also reported that the average age a child is diagnosed with ASD has not changed and remains at greater than 4 years of age with children with milder forms of ASD not being diagnosed until 6 years of age or older. This new data reinforces the need to identify children at increased risk of ASD earlier so they can be assessed, and if warranted, begin beneficial interventions at an earlier age when they have a higher likelihood of success.

IntegraGen Announces Publication of Study in Clinical Cancer Research

IntegraGen announced the publication of a study in Clinical Cancer Research which reports on the ability of the microRNA (miRNA) miR-31-3p to predict progression-free survival in KRAS wild-type (WT) metastatic colorectal cancer (mCRC) patients treated with anti-epidermal growth factor receptor (EGFR) antibodies. The study, entitled 'Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy' examined data from four independent cohorts representing 132 mCRC patients treated with anti-EGFR therapy. Increased expression of miR-31-3p in both fresh frozen and formalin-fixed, paraffin-embedded (FFPE) tissue samples from primary tumors was associated with significantly shorter progression free survival in this patient population.

IntegraGen Enters into Collaborative Agreement with Pfizer

IntegraGen announced that it has entered into an agreement with Pfizer Inc. that provides Pfizer access to evaluate the company's proprietary molecular signature for hepatocellular carcinoma. The 56-gene molecular signature covered by the agreement is intended to predict the clinical prognosis of patients with hepatocellular carcinoma and subcategorize patients into six separate classifications based on the molecular characteristics of their liver tumors. Terms of the agreement were not disclosed.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALINT:FP €5.28 EUR +0.10

ALINT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALINT.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALINT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.8x
Price/Book 29.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTEGRAGEN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at